The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Advances in the treatment of transplant-eligible and ineligible multiple myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses recent advances in the treatment of transplant-eligible and ineligible multiple myeloma. Dr Cerchione highlights novel promising combinations and immunotherapies being explored, and further comments on the importance of achieving measurable residual disease (MRD) negativity as a key endpoint. To conclude, he discusses the potential of optimizing sequencing and maintenance strategies. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
